-
Expanding global access for Firdapse
Firdapse is currently only approved for use in Europe, the United States, and Canada.
Recently, Dydo Pharma teamed up with Catalyst Pharmaceuticals to begin the process of expanding access of Firdapse to Japan.
The process starts with clinical trials which have been ongoing. Phase 3 of the clinical trials began not long ago and hopefully within the next couple of years it will be approved for treatment of LEMS in Japan.
If you want to read more, check out this article on Lambert-Eaton news homepage.
Log in to reply.